Annovis Bio (ANVS) director Form 4/A insider buys update

Annovis Bio, Inc. (ANVS) reported an amended Form 4 for a director showing multiple open-market purchases of common stock on 11/24/2025.

Rhea-AI Filing Summary

Annovis Bio, Inc. (ANVS) reported an amended Form 4 for a director showing multiple open-market purchases of common stock on 11/24/2025. The director bought 1,489 shares at $4.13, 9,200 shares at $3.85, 415 shares at $4.14, and 28,096 shares at $4.15. After these transactions, the director beneficially owned 2,529,739 shares directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust. The amendment states it was filed to correct the share totals shown in column 5 after each reported transaction, with no other changes to the previously reported trades.

Insider Trade Summary

Net Buyer: 39,200 shares

Net Buy 5 txns

Insider Hoffman Michael B

Role Director

Bought 39,200 shs ($160K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,489	$4.13	$6K
Purchase	Common Stock	9,200	$3.85	$35K
Purchase	Common Stock	415	$4.14	$2K
Purchase	Common Stock	28,096	$4.15	$117K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 2,529,739 shares (Direct); Common Stock — 223,357 shares (Indirect, The 2018 Jane and Michael Hoffman Descendants Trust)

Footnotes (1)

1. F1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Annovis Bio (ANVS) report in this Form 4/A?

The filing reports that a director of Annovis Bio (ANVS) purchased multiple lots of common stock on 11/24/2025 in open-market transactions at prices between $3.85 and $4.15 per share.

How many Annovis Bio (ANVS) shares does the director own after the reported transactions?

Following the reported trades, the director beneficially owns 2,529,739 shares of Annovis Bio common stock directly and 223,357 shares indirectly through The 2018 Jane and Michael Hoffman Descendants Trust.

Why is this Annovis Bio (ANVS) Form 4/A labeled as an amendment?

The document is an amendment to a Form 4 filed on November 25, 2025, and it states that the purpose is to correct the totals shown in column 5 after each of the reported transactions, with no other changes made.

What were the purchase prices for the Annovis Bio (ANVS) shares bought by the director?

The director bought Annovis Bio common stock at $4.13, $3.85, $4.14, and $4.15 per share in separate transactions on 11/24/2025.

What type of relationship does the reporting person have with Annovis Bio (ANVS)?

The reporting person is identified as a Director of Annovis Bio, Inc., which is the capacity in which these insider transactions are being reported.

How are the indirectly owned Annovis Bio (ANVS) shares held for the director?

The filing states that 223,357 shares are held in The 2018 Jane and Michael Hoffman Descendants Trust, a family trust formed by the reporting person, who has voting and investment power over those shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 06:59 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Hoffman Michael B

(Last) (First) (Middle)

C/O ANNOVIS BIO, INC.

101 LINDENWOOD DR, SUITE 225

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/24/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/24/2025		P		1,489	A	$4.13	2,492,028	D
Common Stock	11/24/2025		P		9,200	A	$3.85	2,501,228	D
Common Stock	11/24/2025		P		415	A	$4.14	2,501,643	D
Common Stock	11/24/2025		P		28,096	A	$4.15	2,529,739	D
Common Stock								223,357	I	The 2018 Jane and Michael Hoffman Descendants Trust(1)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.

Remarks:

This Amendment to the Form 4 filed on November 25, 2025 is being filed to correct the totals shown in column 5 after each of the reported transactions. No other changes to the previously-reported transactions are being made.

	/s/ Maria Maccecchini Attorney-in-Fact	11/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.